Lisa Bhatt

Lisa Bhatt investigates how doxycycline and other antibiotics that target mitochondria can preferentially eradicate cancer stem cells. Her research has characterized how doxycycline inhibits mitochondrial ribosomal biogenesis in cancer stem cells, which rely on mitochondrial translation for energy production. She investigates combination strategies pairing doxycycline with metabolic inhibitors and conventional cancer treatments to overcome cancer stem cell-driven resistance and recurrence. Her work expands the concept of antibiotic repurposing in oncology beyond antimicrobial to anticancer applications.